title: Assessment of cost-effective antibiotic therapy in the management of infections in cancer patients.
abstract: OBJECTIVE
  To describe the economic benefits of a quality improvement effort directed at optimizing clinical outcome.
  
  
  METHODS
  A before-after observational design was used to evaluate the cost-effectiveness of a consensus approach to antimicrobial therapy.
  
  
  METHODS
  The evaluation was conducted at a cancer research hospital.
  
  
  METHODS
  Oncology patients requiring parenteral antibiotic therapy were consecutively observed.
  
  
  METHODS
  Outcome (clinical and microbiologic response), safety, and cost of therapy were assessed during a baseline period and compared to a period during which the consensus approach was used.
  
  
  METHODS
  The influence of a designated individual, in this case a clinical pharmacist, responsible for promotion of the consensus approach was explored.
  
  
  RESULTS
  The consensus approach in combination with the promotional efforts of the clinical pharmacist was associated with a 13 percent increase in overall clinical response and a reduction of pathogen persistence from 22 to 11 percent. No difference in the average number of adverse effects per patient was observed over the two observation periods. These findings were associated with an estimated $22,000/month cost savings. The consensus approach alone, without benefit of the clinical pharmacist, was not associated with improved therapeutic outcome or cost savings over the same observation periods.
  
  
  CONCLUSIONS
  These data suggest that a consensus approach to antibiotic therapy can be cost-effective. An individual, such as a clinical pharmacist, may add significantly to quality improvement and cost-effective efforts in a hospital setting.
authors.affiliation: Children's Hospital, Buffalo, NY 14222.
authors.forename: M A
authors.initials: MA
authors.lastname: Cimino
authors.forename: C M
authors.initials: CM
authors.lastname: Rotstein
authors.forename: J E
authors.initials: JE
authors.lastname: Moser
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002173:Cancer Care Facilities / Q000191:economics*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D017723:Drug Utilization Review; D017721:Hospital Costs; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D009518:New York; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents